Literature DB >> 6759226

In vivo deactivation of peripheral, hepatic, and pancreatic insulin action in man.

R S Gray, J A Scarlett, J Griffin, J M Olefsky, O G Kolterman.   

Abstract

The in vivo deactivation of insulin action has been studied in 10 lean, nondiabetic subjects using a modification of the euglycemic glucose clamp technique. Following cessation of 40- and 120-mU/m2/min insulin infusions, the serum insulin levels fell to one-half their initial values (mean +/- SE) of 126 +/- 7 and 350 +/- 14 microunits/ml in 7 +/- 1 and 8 +/- 1 min, respectively. The mean incremental glucose disposal rates (IGDR) fell more slowly following discontinuation of the 40- and 120-mU/m2/min insulin infusions, so that the time required for the IGDRs to fall to one-half their initial values (D50 IGDR) were were 42 +/- 5 and 78 +/- 1 min, respectively. Mean hepatic glucose output was totally suppressed during the 40- and 120-mU/m2/min insulin infusions, remained completely suppressed following cessation of the infusions for 50 and 80 mi, and subsequently returned to basal levels. The times required for the HGOs to return to one-half their basal levels (R50 HGO) were 59 +/- 8 and 119 +/- 6 min, respectively. The times required for insulin action to decrease to one-half the initial values in the periphery (D50 IGDR) and in the liver (R50 HGO) were correlated with the preceding steady-state glucose disposal rates in individual subjects (r = 0.75, P less than 0.001 and r = 0.58, P less than 0.05, respectively). The suppression of endogenous insulin secretion by exogenous insulin infusions was also studied in 4 subjects during a total of 5 euglycemic glucose clamps; the mean basal serum C-peptide level was 0.67 +/- 0.24 pmol/ml before administration of the exogenous insulin, fell to 0.34 +/- 0.17 pmol/ml during the steady-state phase of the study, and remained suppressed throughout the duration of the deactivation phase of the glucose clamp. Residual pancreatic insulin secretory capacity was demonstrated by a rise in the serum C-peptide level to 1.77 +/- 0.50 pmol/ml at 120 min following a standardized meal given at the conclusion of the deactivation phase of the glucose clamp. These results demonstrate that the deactivation of insulin action in the periphery, liver, and pancreas lags behind the disappearance of insulin from the plasma. The mechanisms responsible for this lag in in vivo deactivation are not known for certain, but may include slower clearance of insulin form tissue compartments than form the plasma, the necessity for the target tissues to generate specific deactivation signals, or a slow rate of decay of saturable steps in the cellular activation process.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759226     DOI: 10.2337/diab.31.10.929

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  11 in total

1.  In vivo stimulation of the insulin receptor kinase in human skeletal muscle. Correlation with insulin-stimulated glucose disposal during euglycemic clamp studies.

Authors:  G R Freidenberg; S L Suter; R R Henry; D Reichart; J M Olefsky
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects.

Authors:  A D Baron; O G Kolterman; J Bell; L J Mandarino; J M Olefsky
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

3.  Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM.

Authors:  A Vaag; F Alford; F L Henriksen; M Christopher; H Beck-Nielsen
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

4.  In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects.

Authors:  R Prager; P Wallace; J M Olefsky
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

5.  Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.

Authors:  R N Bergman; R Prager; A Volund; J M Olefsky
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

6.  Pharmacodynamics of insulin following intravenous and enteral administrations of porcine-zinc insulin to rats.

Authors:  R J Schilling; A K Mitra
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

7.  Influence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabetics.

Authors:  R S Gray; P Cowan; U di Mario; R A Elton; B F Clarke; L J Duncan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-08

8.  Evidence that hyperglycaemia per se does not inhibit hepatic glucose production in man.

Authors:  M J Müller; K J Acheson; A G Burger; E Jequier
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1990

9.  Differing effects of antiinsulin serum and antiinsulin receptor serum on 123I-insulin metabolism in rats.

Authors:  J C Sodoyez; F Sodoyez Goffaux; R von Frenckell; C J De Vos; S Treves; C R Kahn
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

10.  Neuroendocrine responses to glucose ingestion in man. Specificity, temporal relationships, and quantitative aspects.

Authors:  T F Tse; W E Clutter; S D Shah; J P Miller; P E Cryer
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.